TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01863056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-Stand Desk
Description: Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
Study: NCT00857259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 5 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 5 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg administered by intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg administered by intravitreal injection
Study: NCT04838028

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia
Study: NCT00501215

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Polysomnography (PSG)
Description: 2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview
Study: NCT04838028

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia
Study: NCT03684265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Capsule (Test)
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Tablet (Reference)
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Tablet (Reference)
Description: single dose
Study: NCT03630224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte Viaflo
Description: Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
Study: NCT04838028

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia
Study: NCT03630224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9%
Description: Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
Study: NCT04838028

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TEP
Description: Laparoscopic totally extraperitoneal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia

Intervention type: PROCEDURE
Intervention: TAPP
Description: Laparoscopic transabdominal mesh repair of groin hernia
Study: NCT03037034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forcep
Description: Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current.
Study: NCT00317642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine (IV formulation)
Description: clofarabine (IV formulation) infusion 40mg/m\^2 / day up to 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo (sodium Chloride) 1-hour IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: cytarabine IV infusion 1g/m\^2/day for up to 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: cytarabine IV infusion 1g/m\^2/day for up to 3 cycles
Study: NCT00501215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Description: 2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview
Study: NCT01962714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loving-Kindness Meditation
Description: 12-week loving-kindness meditation course

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: 12-week CPT course
Study: NCT00895518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) Therapy
Description: Three PE sessions lasting 1 hour each, delivered 1 week apart
Study: NCT00680186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: PRN (to maintain a target INR of 2.0-3.0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150mg bid
Study: NCT00094458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab infusion; AZA placebo caps
Description: Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
Study: NCT02526719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple Delay surgery
Description: The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
Study: NCT00094458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infliximab (IFX) infusion; azathioprine (AZA) caps
Description: AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab (IFX) placebo infusion; azathioprine (AZA) caps
Description: AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
Study: NCT03393416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I
Description: The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 antibody
Description: Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study.
Study: NCT02467647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLJDT
Study: NCT03416738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantically focused treatment
Description: Tasks are as follows:~1. Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~2. Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~3. Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phonologically focused treatment
Description: Tasks are as follows:~1. Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~2. Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~3. The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation.
Study: NCT03243084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XCSITE100 Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
Study: NCT03183310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine
Description: an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal stimulation probe
Description: The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal stimulation probe
Description: The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
Study: NCT00744614

Intervention type: PROCEDURE
Intervention: Capnography
Description: A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
Study: NCT02104934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Study: NCT02066337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozonated olive oil gel
Study: NCT01642524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hypertonic saline mixed Dextran
Description: single dose administered intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: placebo - saline solution
Study: NCT01747278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
Study: NCT03966105

Intervention type: DIAGNOSTIC_TEST
Intervention: HE and Congo red staining
Description: Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
Study: NCT02456870

Intervention type: OTHER
Group type: OTHER
Intervention: Overfeeding
Description: Consumption of 40% excess calories for 7 consecutive days

Intervention type: OTHER
Group type: OTHER
Intervention: Overfeeding
Description: Consumption of 40% excess calories for 7 consecutive days
Study: NCT02852148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTICOAT
Description: ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
Study: NCT01892098

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulfate
Description: 9mg elemental zinc via 23mg zinc sulfate/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose pill given as placebo
Study: NCT00667251

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib ditosylate
Description: 1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
Study: NCT04424836

Intervention type: DEVICE
Intervention: high flow nasal cannula device
Description: device is supplying oxygen with heated and humidified air in a high flow rate
Study: NCT01071993

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
Study: NCT01563640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: permethrin insecticide
Description: commercial permethrin insecticide impregnation of clothing before transmission season

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: washing
Description: normal washing of school uniforms, without permethrin insecticide impregnation
Study: NCT03892330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytetracycline/ Cyclophosphamide
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytetracycline/ Cyclophosphamide
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytetracycline/ Cyclophosphamide
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytetracycline/ Cyclophosphamide
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmorubicin
Description: The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirarubicin
Description: The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Study: NCT01426399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444
Description: LC15-0444 50mg qd (8 days once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg bid (8 days twice daily)
Study: NCT01071993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
Study: NCT01426399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444+Metformin
Description: LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
Study: NCT03172520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APS electrode
Description: The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facial Nerve Monitor
Description: The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
Study: NCT01237106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVM
Description: all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
Study: NCT05117047

Intervention type: PROCEDURE
Intervention: liver resection
Description: After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
Study: NCT03106506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
Study: NCT05117047

Intervention type: PROCEDURE
Intervention: liver resection
Description: After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.

Intervention type: PROCEDURE
Intervention: liver resection
Description: After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
Study: NCT02287324

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation
Study: NCT03106506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Description: Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
Study: NCT03912025

Intervention type: OTHER
Intervention: Relationship between positive mindset and exercise capacity
Description: No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes

Intervention type: OTHER
Intervention: Relationship between positive mindset and exercise capacity
Description: No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
Study: NCT03227562

Intervention type: DRUG
Group type: OTHER
Intervention: RisperiDONE 0.5 MG
Description: To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.

Intervention type: DRUG
Group type: OTHER
Intervention: RisperiDONE 0.5 MG
Description: To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
Study: NCT01990924

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 15 FPS
Description: X-ray pictures

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 7.5 FPS
Description: X-ray pictures
Study: NCT01771718

Intervention type: DEVICE
Intervention: MPTflex-multiphoton microscopy-based tomograph.
Description: non-invasive optical biopsy